Physician profile
Ali Abedi
NPI 1346566312
$268,718.10
in general payments reported to CMS, 2019-2025
39 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,598 · 2020: $43K · 2021: $78K · 2022: $80K · 2023: $33K · 2024: $17K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Education: $14K · Food and Beverage: $6,439 · Travel and Lodging: $4,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,750.00 |
| Education | $14,000.00 |
| Food and Beverage | $6,439.34 |
| Travel and Lodging | $4,204.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $259,210.22 | 2019-2025 | Da Vinci Sp, Da Vinci Surgical System |
| Pulmonx Corporation | $1,704.58 | 2019-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Glaxosmithkline, LLC. | $1,556.58 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Galvanize Therapeutics, INC | $786.79 | 2022-2025 | Aliya System |
| Mylan Specialty L.P. | $753.55 | 2019-2024 | Yupelri |
| Genzyme Corporation | $637.52 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.72 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $425.34 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Olympus America INC. | $328.74 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $287.97 | 2019-2021 | |
| Boston Scientific Corporation | $279.42 | 2021-2024 | Exalt Model D |
| Steris Corporation | $227.69 | 2025 | |
| Electromed, INC. | $195.71 | 2022-2024 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $193.87 | 2019-2020 | |
| Philips North America LLC | $182.44 | 2019-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Abedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.